Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 24 2021 - 4:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2021 (No. 2)
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive
offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On August 24, 2021, Cellect Biotechnology Ltd. (the
“Company”) issued a press release entitled “Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating
Results.” In addition, on the same day, the Company issued unaudited interim consolidated financial statements as of June 30, 2021,
together with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2021.
Exhibits 99.2 and 99.3 to this Form 6-K and the statements
under “Second Quarter 2021 Financial Results,” “Forward Looking Statements,” and the accompanying financial statements
included in Exhibit 99.1 to this Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on
Form S-8 (Registration Nos. 333-214817, 333-220015, 333-225003 and 333-232230) and on Form F-3 (Registration Nos. 333-219614 and 333-229083).
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: August 24, 2021
|
CELLECT BIOTECHNOLOGY, LTD.
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Eyal Leibovitz
Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2023 to Apr 2024